
SENATE COMMITTEE AMENDMENTS

2025 Regular Session

Amendments proposed by Senate Committee on Insurance to Engrossed House Bill No. 408
by Representative Dickerson

AMENDMENT NO. 1

On page 1, line 5, after "definitions;" insert "to provide for applicability;"

AMENDMENT NO. 2

On page 1, between line 6 and line 7, insert the following:

"Section 1. The legislature hereby finds and affirms the following:

(1) Symptoms of PANS, PANDAS, and other types of AE cause disruption to a child's neurological functioning and may appear in episodes of anxiety, incontinence, seizures, confusion, depression, tics, personality changes, declines in school performance, and changes in sensory sensitivities. The symptoms may worsen or extend with each episode.

(2) Younger children are often misdiagnosed as having autism and many affected children meet criteria for state disability services because their symptoms are not solely attributable to mental illness.

(3) Studies have found several therapies and treatments to be effective in resolving symptoms, including but not limited to antibiotic therapy, intravenous immunoglobulin treatments, antidepressant medications, cognitive behavioral therapies, and plasma exchange.

(4) Early treatment is important to prevent permanent brain injury and nervous system damage, cognitive decline, and mental illness that may persist into adulthood and death because the conditions are potentially fatal."

AMENDMENT NO. 3

On page 1, line 7, change "Section 1." to "Section 2."

AMENDMENT NO. 4

On page 1, delete lines 11 through 19 in their entirety

AMENDMENT NO. 5

On page 2, delete lines 1 through 7 in their entirety

AMENDMENT NO. 6

On page 2, line 8, change "B." to "A."

AMENDMENT NO. 7

On page 2, between lines 13 and 14, insert the following:

"B.(1) In making determinations of coverage for PANDAS, PANS, and other types of AE, insurers may consider but not require strict adherence to other treatment options or recommendations developed by a medical professional consortium convened for the purposes of researching, identifying, and publishing best practice standards for diagnosis and treatment of these disorders, such as the PANDAS Physician Network. The treatment should be based on evidence of positive patient outcomes.

(2) A health coverage plan may limit intravenous immunoglobulin treatments to no more than three monthly courses of treatment, unless additional treatment is deemed medically necessary based on a clinical review using such guidelines."

1 AMENDMENT NO. 8

2 On page 2, line 22, after "include the" change "office of group" to "Office of Group"

3 AMENDMENT NO. 9

4 On page 2, at the beginning of line 23, change "benefits" to "Benefits"

5 AMENDMENT NO. 10

6 On page 3, after line 4, insert the following:

7 "Section 3. The provisions of this Act apply to any new policy, contract, or health coverage
8 plan issued on or after January 1, 2026. Any policy, contract, or health coverage plan in
9 effect prior to January 1, 2026, shall convert to conform to the provisions of this Act on or
10 before the renewal date, but no later than January 1, 2027."